Sign up for our complimentary
weekly e-journal

Main Newsletter
Mastery Series
Therapy Series
 
Bookmark and Share | Print Article | Items for the Week Previous | All Articles This Week | Next
This article originally posted and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Insulin Pumps vs. Multiple Daily Injections (MDI): Which is Better?

Can insulin pumps reduce glycemic variability in type 1 diabetes?...

Advertisement

A new cross-sectional observational cohort study looked at continuous subcutaneous insulin infusion (CSII), aka insulin pump, versus multiple daily injections (MDI) to determine which insulin delivery system resulted in less blood glucose variability in type 1 pediatric diabetes patients. Large variations in blood glucose have been implicated in causing cardiovascular complications which can lead to a number of comorbidities and mortality in diabetics.

This recent study was performed in 48 pediatric type 1 diabetes patients, 22 of whom used an insulin pump while the others used MDI. The patients were followed for 3 days using continuous blood glucose monitoring; blood glucose variability was also assessed in 2 consecutive 24 hour periods by a surrogate marker, F2-isoprostanes and/or urinary prostaglandin F2 excretion. Results showed that standard deviation of mean glucose concentration (p<0.05) and insulin requirements, HDL-cholesterol, the mean of glycemic excursions (p<0.01) were statistically lower in the insulin pump group.

While the study did not specifically look at the impact of insulin pump use vs. MDI on cardiovascular complications, one could assume that limiting glucose variations would have a positive impact on the cardiovascular system. The study was small and the MDI groups were even smaller. Each MDI group had somewhere between 4 - 9 patients who were assigned certain insulins whether that be normal, fast acting, basal and/or a combo of thereof. Further research and longitudinal studies would be of benefit to better assess association of CSII therapy versus MDI therapy and their impact on cardiovascular, co-morbidity, and mortality outcomes.

Practice Pearls:

  • Large variations in plasma glucose have been implicated in causing cardiovascular complications.
  • Patients with type 1 diabetes are significantly more likely to develop cardiovascular disease versus their peers.
  • Using continuous subcutaneous insulin infusion seems to be associated with reduced variations in blood glucose levels versus using multiple daily injections in type 1 diabetes.

Schreiver, C. et al. Glycemic Variability in Pediatric Patients With Type 1 Diabetes on Continuous Subcutaneous Insulin Infusion (CSII) or Multiple Daily Injections (MDI). Clin Endocrinol. 2013;79(5):641-647 

Advertisement


 

Bookmark and Share | Print | Category | Home

This article originally posted 12 December, 2013 and appeared in  BG ControlMedical DevicesInsulinGlucose MonitoringIssue 707

Past five issues: Diabetes Clinical Mastery Series Issue 242 | Issue 782 | Diabetes Clinical Mastery Series Issue 241 | issue 781 | Diabetes Clinical Mastery Series Issue 240 |

2015 Most Popular Articles:

Neuropathy Due to Vitamin B-12 Deficiency, Not Diabetes
Posted April 30, 2015
What Is the Medicare Diabetes Prevention Act?
Posted May 08, 2015
Is Diet or Exercise the Best Way to Reduce Diabetes Risk?
Posted May 15, 2015
Metformin Reported in Use with Only 3.7% of Those with Prediabetes
Posted April 30, 2015
Statin Therapy Associated with 46% Higher Risk of Type 2 Diabetes
Posted April 23, 2015
Summary of Standards of Care for Diabetes for Primary Care
Posted April 30, 2015
SGLT-2 Inhibitors: Teach from the Start and Manage Expectations
Posted May 03, 2015
Treating Sleep Apnea with CPAP Nightly Can Lower Diabetes Risk
Posted May 08, 2015
Fish Oil May Help with Diabetic Neuropathy
Posted May 15, 2015
How to Lower the Risk of Getting Diabetes by Up to 25%
Posted May 08, 2015


Browse by Feature Writer & Article Category.
A. Lee Dellon, MD | Aaron I. Vinik, MD, PhD, FCP, MACP | Beverly Price | Charles W Martin, DD | Derek Lowe, PhD | Dr. Brian Jakes, Jr. | Dr. Fred Pescatore | Dr. Tom Burke, Ph.D | Eric S. Freedland | Evan D. Rosen | Ginger Kanzer-Lewis | Greg Milliger | Kristina Sandstedt | Laura Plunkett | Leonard Lipson, M.A. | Louis H. Philipson | Maria Emanuel Ryan, DDS, PhD | Marilyn Porter, RD, CDE | Melissa Diane Smith | Michael R. Cohen, RPh, MS, ScD, FASHP | Paul Chous, M.A., OD | Philip A. Wood PhD | R. Keith Campbell, Professor, B.Pharm, MBA, CDE | Richard K. Bernstein, MD | Sheri R. Colberg PhD | Sherri Shafer | Stanley Schwartz, MD, FACP, FACE | Steve Pohlit | Steven V. Edelman, M.D. | Timothy S. Hollingshead |

Cast Your Vote
Do you believe that we could have a bionic pancreas by 2017?
CME/CE of the Week
Diabetes Nutrition Recommendations: Obesity and Diabetes Prevention
Judith Wylie-Rosett, EdD, RD

Category: Nutrition
Credits: .5



Search Articles On Diabetes In Control